INSM - Insmed Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Insmed Incorporated

Building 10
10 Finderne Avenue
Bridgewater, NJ 08807
United States
908-977-9900
http://www.insmed.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees373

Key Executives

NameTitlePayExercisedYear Born
Mr. William H. Lewis J.D.Pres, CEO & Chairman1.24MN/A1969
Ms. Christine A. Pellizzari J.D.Chief Legal Officer & Corp. Sec.730.61kN/A1968
Mr. Roger AdsettChief Commercial Officer773.14kN/A1969
Dr. Paul D. StreckAdvisor733.67kN/A1964
Mr. John Goll IIIChief Accounting OfficerN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Insmed Incorporated, a global biopharmaceutical company, focuses on the development and commercialization of therapies for patients with serious and rare diseases. Its first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Its earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that offers a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Corporate Governance

Insmed Incorporated’s ISS Governance QualityScore as of April 1, 2019 is 6. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 10; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.